ONE WORLD TRADE CENTER, NEW YORK, NY
Announces Pricing of $700 Million Upsized Public Offering
Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
Shareholders Approve Amendment to 2025 Equity Incentive Plan
Other Events
Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
Reports First Quarter 2026 Financial Results and Recent Highlights
Investor Presentation
Reports Full-Year 2025 Financial Results and Business Updates
Q1
FY 2024
Q3
Q2
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
Definitive Additional Information Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Prospectus filed pursuant to Rule 424(b)(7)
Correspondence
Submission Upload